2021
Iron Infusion Reactions: Risk Factors and Real-World Experience
Butt A, Muradashvili T, Soliman S, Goshua G, Burns A, Bar N, Martin K, Borgman G, Bona R, Lee A, Neparidze N. Iron Infusion Reactions: Risk Factors and Real-World Experience. Blood 2021, 138: 4154. DOI: 10.1182/blood-2021-151048.Peer-Reviewed Original ResearchInfusion-related reactionsSeverity of IRRsHistory of CVDHistory of allergyCardiovascular diseaseBeta blockersOral ironPatient characteristicsRisk factorsLower oddsGreater oddsExact testAngiotensin-converting enzyme inhibitor useAssociation of CVDYale-New Haven HospitalEnzyme inhibitor useFirst-line therapyHeavy menstrual bleedingRetrospective chart reviewMajority of patientsAnti-inflammatory effectsMajor adverse effectsIron deficiency anemiaMultivariable regression analysisSeverity of reactionsRacial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database
Calip G, Ascha M, Wang X, Pierre A, Maignan K, Wadé N, Leng S, Seymour E, Chiu B, Sweiss K, Patel P, Neparidze N. Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database. Blood 2021, 138: 4121. DOI: 10.1182/blood-2021-152774.Peer-Reviewed Original ResearchReal-world progression-free survivalHigh-risk cytogenetic abnormalitiesCurrent equity holderFlatiron HealthBlack patientsWhite patientsMultiple myelomaMM patientsCytogenetic abnormalitiesClinical characteristicsHazard ratioAge groupsAutologous stem cell transplantationAdvisory CommitteeAdult MM patientsCytogenetic risk stratificationOlder black patientsTechnology-enabled abstractionYoung black patientsAdjusted hazard ratioRetrospective cohort studyFirst-line therapyFirst-line treatmentHigh-risk subsetProgression-free survival
2020
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents
Giri S, Huntington SF, Wang R, Zeidan AM, Podoltsev N, Gore SD, Ma X, Gross CP, Davidoff AJ, Neparidze N. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Advances 2020, 4: 2245-2253. PMID: 32442299, PMCID: PMC7252537, DOI: 10.1182/bloodadvances.2019001425.Peer-Reviewed Original ResearchConceptsHigh-risk chromosomal abnormalitiesOverall survivalMultiple myelomaChromosome 1 abnormalitiesCox proportional hazards regression modelHigh-risk multiple myelomaProportional hazards regression modelsFlatiron Health databaseR-ISS stageMedian overall survivalFirst-line therapyDays of diagnosisInferior overall survivalInternational Staging SystemKaplan-Meier methodSurvival of patientsWorse overall survivalLog-rank testHazards regression modelsCommon genetic aberrationsElectronic health recordsEligible patientsContemporary cohortImmunomodulatory agentsStaging system